Changes

====Other Cancers====

====Other Cancers====

''WT1'' overexpression enhances ovarian cancer cell proliferation in vitro (Liu et al., 2014). Higher expression of ''WT1'' is associated with higher stage in ovarian cancer and more aggressive clinical features, but evidence for the use of WT1 expression as a prognostic marker for overall survival is mixed (Köbel et al., 2008; Liu et al., 2014; Netinatsunthorn et al., 2006). A meta-analysis of solid cancers including breast cancer, endometrial cancer, colorectal cancer, and glioma among others found that ''WT1'' expression correlated with worse clinical outcomes such as overall and disease-free survival (Qi et al., 2015). ''WT1''-targeting therapies are being explored (Koido et al., 2014; Sawada et al., 2016; Shirakata et al., 2012).

''WT1'' overexpression enhances ovarian cancer cell proliferation ''in vitro'' (Liu et al., 2014). Higher expression of ''WT1'' is associated with higher stage in ovarian cancer and more aggressive clinical features, but evidence for the use of WT1 expression as a prognostic marker for overall survival is mixed (Köbel et al., 2008; Liu et al., 2014; Netinatsunthorn et al., 2006). A meta-analysis of solid cancers including breast cancer, endometrial cancer, colorectal cancer, and glioma among others found that ''WT1'' expression correlated with worse clinical outcomes such as overall and disease-free survival (Qi et al., 2015). ''WT1''-targeting therapies are being explored (Koido et al., 2014; Sawada et al., 2016; Shirakata et al., 2012).

==Common Alteration Types==

==Common Alteration Types==